Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2309 ARTÍCULOS , VIENDO DEL 511 AL 525

Ushering in a New Era of Alzheimer Disease Therapy

Widera EW, Brangman SA, Chin NA.

JAMA. 2023 Aug 8;330(6):503-504. doi: 10.1001/jama.2023.11701.

Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease

Rabinovici GD, La Joie R.

JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703.

Novel Alzheimer Disease Treatments and Reconsideration of US Pharmaceutical Reimbursement Policy

Rosenthal MB.

JAMA. 2023 Aug 8;330(6):505-506. doi: 10.1001/jama.2023.11702.

A critical review on the role of nanotheranostics mediated approaches for targeting β amyloid in Alzheimer's

Rastogi V, Jain A, Kumar P, Yadav P, Porwal M, Chaturvedi S, Chandra P, Verma A.

J Drug Target. 2023 Aug;31(7):725-744. doi: 10.1080/1061186X.2023.2238250. Epub 2023 Jul 19.

Autonomic nervous system flexibility for understanding brain aging

Lin FV, Heffner KL.

Ageing Res Rev. 2023 Sep;90:102016. doi: 10.1016/j.arr.2023.102016. Epub 2023 Jul 17.

Signal Pathways and Intestinal Flora through Trimethylamine N-oxide in Alzheimer's Disease

Zhang Y, Jian W.

Curr Protein Pept Sci. 2023;24(9):721-736. doi: 10.2174/1389203724666230717125406.

Exploring New Vista for Alzheimer's Disease Drug Targets (Part II)

Bolinger AA, Zhou J.

Curr Top Med Chem. 2023;23(13):1211-1213. doi: 10.2174/156802662313230626121232.

Natural antioxidants that act against Alzheimer's disease through modulation of the NRF2 pathway: a focus on their molecular mechanisms of action

Sidiropoulou GA, Metaxas A, Kourti M.

Front Endocrinol (Lausanne). 2023 Jul 3;14:1217730. doi: 10.3389/fendo.2023.1217730. eCollection 2023.

Integration of genome-wide association studies (GWAS) and microbiome data highlights the impact of sulfate-reducing bacteria on Alzheimer's disease

Guo X, Zhang X, Tang P, Chong L, Li R.

Age Ageing. 2023 Jul 1;52(7):afad112. doi: 10.1093/ageing/afad112.

Targeted Regulation of Intracellular Signal Transduction: A New Paradigm for Stimulation of Neurogenesis in Alzheimer's Disease

Zyuz'kov G.

Curr Drug Targets. 2023;24(10):777-780. doi: 10.2174/1389450124666230719104808.

Expression and function of estrogen receptors and estrogen-related receptors in the brain and their association with Alzheimer's disease

Sato K, Takayama KI, Inoue S.

Front Endocrinol (Lausanne). 2023 Jul 4;14:1220150. doi: 10.3389/fendo.2023.1220150. eCollection 2023.

Microbiota dysbiosis caused by dietetic patterns as a promoter of Alzheimer's disease through metabolic syndrome mechanisms

Navalón-Monllor V, Soriano-Romaní L, Silva M, de Las Hazas ML, Hernando-Quintana N, Suárez Diéguez T, Esteve PM, Nieto JA.

Food Funct. 2023 Aug 14;14(16):7317-7334. doi: 10.1039/d3fo01257c.

Amyloid-Lowering Monoclonal Antibodies for the Treatment of Early Alzheimer's Disease

Leisher S, Bohorquez A, Gay M, Garcia V, Jones R, Baldaranov D, Rafii MS.

CNS Drugs. 2023 Aug;37(8):671-677. doi: 10.1007/s40263-023-01021-8. Epub 2023 Jul 20.

The aquaporin-4 water channel and updates on its potential as a drug target for Alzheimer's disease

Silverglate B, Gao X, Lee HP, Maliha P, Grossberg GT.

Expert Opin Ther Targets. 2023 Jul-Dec;27(7):523-530. doi: 10.1080/14728222.2023.2240017. Epub 2023 Jul 27.

Patent analysis of novel therapeutic approaches for treating Alzheimer's disease 2018-2023

Saleem F, Naz F, Khan KM.

Pharm Pat Anal. 2023 May;12(3):91-94. doi: 10.4155/ppa-2023-0020. Epub 2023 Jul 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias